Detalhe da pesquisa
1.
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
Am J Hematol
; 95(12): 1553-1561, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32894785
2.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(6): 781-794, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31097405
3.
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
Br J Haematol
; 176(6): 908-917, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28211054
4.
The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma.
Eur J Haematol
; 98(5): 508-516, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28160316
5.
Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods.
Qual Life Res
; 26(11): 2931-2947, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28752440
6.
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.
Biol Blood Marrow Transplant
; 22(6): 1009-1016, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26827659
7.
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
Br J Haematol
; 193(3): e19-e22, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33715154
8.
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
Br J Haematol
; 170(3): 336-48, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25891006
9.
Is the revised International staging system for myeloma valid in a real world population?
Br J Haematol
; 180(3): 451-454, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27734463
10.
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.
Eur J Haematol
; 90(5): 420-5, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23294279
11.
Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics.
Cancers (Basel)
; 15(2)2023 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36672411
12.
GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death.
Blood
; 115(19): 3939-48, 2010 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-20190189
13.
Risk of relapse of multiple myeloma following kidney transplantation.
Clin Kidney J
; 12(2): 216-223, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30976399
14.
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5.
Oncol Ther
; 5(1): 31-40, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28680953
15.
The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England.
Haematologica
; 91(10): 1400-4, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17018393
16.
Life-threatening motor neurotoxicity in association with bortezomib.
Haematologica
; 91(7): 1001, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16757419
17.
The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma.
Haematologica
; 90(12): 1711-3, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16330454
18.
Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales.
Eur J Health Econ
; 14(3): 507-14, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22572968
19.
Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
Cancer Treat Rev
; 37(4): 266-83, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20863623
20.
Cost-effectiveness of lenalidomide in multiple myeloma.
Expert Rev Pharmacoecon Outcomes Res
; 10(3): 229-38, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20545587